H.C. Wainwright initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $20.00

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition's commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer's disease. Ms. Pesa brings 25 years of pharmaceutic

Key Highlights ZUNVEYL Launch Momentum: Completed the first quarter of ZUNVEYL commercialization, achieving approximately $2 million in net product revenues year-to-date. Advancing ALPHA-1062: Completed pre-clinical Bomb Blast study in collaboration with the U.S. Department of Defense and the Seattle Institute of Biomedical and Clinical Research. Strong Balance Sheet: Cash and cash equivalents of $39.4 million as of June 30, 2025, supporting an estimated cash runway of approximately two years at the current utilization rate. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company") today announced its financial results for the second quarter ended June 30, 2025.

Conference Call Scheduled for August 14, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the second quarter on August 14, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: Participant Listening: 1-877-407-9039 or 1-201-689-8470 or https://callme.viavid.com/viavid/?callme=true&passcode=13752398&h=true&info=company&r=true&B=6 - Participant

Launched ZUNVEYL (benzgalantamine) to US market on March 17, 2025 Secured business development licensing revenues of $2.6M for partnership with CMS Pharma Cash and cash equivalents of $45.5 million as of March 31, 2025, compared to $48.6 million as of December 31, 2024. At current cash utilization rates, the Company expects a cash runway of approximately two years. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company") today announced its financial results for the first quarter ended March 31, 2025. "We closed the quarter on a strong note, launching ZUNVEYL® to the long-term care market," said Michael McFadden, Chief Executive Officer. "We feel that the company is

Conference Call Scheduled for May 15, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the link below 15 minutes prior to the schedul

 Raised $52.8 million in gross proceeds in Q4 2024 to support the upcoming ZUNVEYL commercial launch and Nasdaq uplisting (symbol: ACOG). Completed commercial manufacturing to support the ZUNVEYL launch. Successfully completed the first phase of a pre-clinical bomb-blast study funded by a Department of Defense grant, demonstrating benzgalantamine's efficacy and safety in treating head trauma from simulated bomb blasts. Cash and cash equivalents of $48.6 million as of December 31, 2024, compared to $3.7 million as of September 30, 2024 and $1.4 million as of December 31, 2023. At current cash utilization rates, the Company expects a cash runway of approximately two years. Alpha Cogn

Conference Call Scheduled for March 31, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the lin

Alpha Cognition Inc. (NASDAQ:ACOG) (CSE:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended September 30, 2024, and provided a corporate update. "The FDA approval of ZUNVEYL represents an important breakthrough for patients with Alzheimer's disease. Alpha Cognition is focused on commercial preparation in the US market and ex-US licensing opportunities to bring this important therapy to market. The team is adding important expertise in marketing, sales, product reimbursement, and medical to bring ZUNVEYL to patients in

Key Highlights ZUNVEYL Launch Momentum: Completed the first quarter of ZUNVEYL commercialization, achieving approximately $2 million in net product revenues year-to-date. Advancing ALPHA-1062: Completed pre-clinical Bomb Blast study in collaboration with the U.S. Department of Defense and the Seattle Institute of Biomedical and Clinical Research. Strong Balance Sheet: Cash and cash equivalents of $39.4 million as of June 30, 2025, supporting an estimated cash runway of approximately two years at the current utilization rate. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company") today announced its financial results for the second quarter ended June 30, 2025.

Conference Call Scheduled for August 14, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the second quarter on August 14, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: Participant Listening: 1-877-407-9039 or 1-201-689-8470 or https://callme.viavid.com/viavid/?callme=true&passcode=13752398&h=true&info=company&r=true&B=6 - Participant

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" [ACI], or the "Company"), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced China Medical System Holdings Limited (CMS) New Drug Application (NDA) for ZUNVEYL has been accepted by the National Medical Products Administration of China (NMPA) for review for the treatment of mild-to-moderate Alzheimer's dementia. "We are pleased to announce the NMPA acceptance of the ZUNVEYL New Drug Application, marking a significant milestone in our mission to bring innovative treatments to patients in need," said Michael McFadden, Chief Executive Officer of Alpha Cognition. "This accept

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company"), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the Alzheimer's Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will share the following poster presentations: Bioequivalence of ZUNVEYL, a Galantamine Prodrug to Galantamine Hydrobromide Extended-Release Demonstrated Under Steady State Conditions (Poster #107147) - July 27 Bioequivalence of ZUNVEYL, a Galantamine Prodrug to Galantamine Hydrobromide Immediate-Release Demonstrated Under

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" [ACI], or the "Company"), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced preclinical data supporting the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The data provides additional evidence of benefits of ALPHA-1062, in the treatment of mTBI resulting from repetitive blast trauma, a highly relevant military injury. Service related mTBI results in a high incidence of persistent physical and emotional challenges for patients, impacting their quality of life and that of their families. Additionally, a history of mTBI increases

Launched ZUNVEYL (benzgalantamine) to US market on March 17, 2025 Secured business development licensing revenues of $2.6M for partnership with CMS Pharma Cash and cash equivalents of $45.5 million as of March 31, 2025, compared to $48.6 million as of December 31, 2024. At current cash utilization rates, the Company expects a cash runway of approximately two years. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company") today announced its financial results for the first quarter ended March 31, 2025. "We closed the quarter on a strong note, launching ZUNVEYL® to the long-term care market," said Michael McFadden, Chief Executive Officer. "We feel that the company is

Conference Call Scheduled for May 15, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the link below 15 minutes prior to the schedul

Alpha Cognition Inc. (NASDAQ:ACOG) (the "Company" or "Alpha Cognition") today announced three upcoming presentations at the 2025 Alzheimer's Association International Conference (the "AAIC"), taking place July 27–31, 2025 in Toronto, Canada. The presentations will highlight clinical studies supporting ZUNVEYL (benzgalantamine), the Company's lead product and a novel galantamine prodrug approved by the FDA in July 2024 and commercially launched in March 2025. The studies demonstrated bioequivalence to galantamine IR and ER and were integral to the NDA submission and approval. "We're excited to share data that underscore ZUNVEYL's potential to deliver meaningful clinical benefit to patients

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

 Raised $52.8 million in gross proceeds in Q4 2024 to support the upcoming ZUNVEYL commercial launch and Nasdaq uplisting (symbol: ACOG). Completed commercial manufacturing to support the ZUNVEYL launch. Successfully completed the first phase of a pre-clinical bomb-blast study funded by a Department of Defense grant, demonstrating benzgalantamine's efficacy and safety in treating head trauma from simulated bomb blasts. Cash and cash equivalents of $48.6 million as of December 31, 2024, compared to $3.7 million as of September 30, 2024 and $1.4 million as of December 31, 2023. At current cash utilization rates, the Company expects a cash runway of approximately two years. Alpha Cogn

10-Q - Alpha Cognition Inc. (0001655923) (Filer)

424B3 - Alpha Cognition Inc. (0001655923) (Filer)

S-3 - Alpha Cognition Inc. (0001655923) (Filer)

424B3 - Alpha Cognition Inc. (0001655923) (Filer)

EFFECT - Alpha Cognition Inc. (0001655923) (Filer)

S-3 - Alpha Cognition Inc. (0001655923) (Filer)

8-K - Alpha Cognition Inc. (0001655923) (Filer)

10-Q - Alpha Cognition Inc. (0001655923) (Filer)

DEF 14A - Alpha Cognition Inc. (0001655923) (Filer)

8-K - Alpha Cognition Inc. (0001655923) (Filer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

3 - Alpha Cognition Inc. (0001655923) (Issuer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)

4 - Alpha Cognition Inc. (0001655923) (Issuer)